The case for regulatory approval of amyloid‐lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence is a research paper published in Alzheimer s & Dementia (2024). On theSindex it has a DataRank of 0. It has been cited 29 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIGMS NIH HHS
Grant: P20 GM109025
NIA NIH HHS
Grant: R35 AG071476
MeSH Terms
Keywords